Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Epidemiology of Schizophrenia in Bulgaria

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: September 24, 2009
Last updated: February 2, 2010
Last verified: February 2010

The purpose of this study is to provide accurate, reliable information on schizophrenia clinical management in order to detect unmet medical needs of this disease in terms of:

  • Patient characteristics.
  • Diagnostic and treatment approaches: initial and subsequent.


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Epidemiological Study to Describe Approaches in Diagnosis, Treatment and Social Functioning of Schizophrenic Patients in Bulgaria

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Enrollment: 440
Study Start Date: September 2009
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary Care Clinic

Inclusion Criteria:

  • Patients with schizophrenia
  • Above 18 years
  • Signed Informed consent

Exclusion Criteria:

  • Below 18 years
  • Consent refused
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00984373

Research Site
Burgas, Bulgaria
Research Site
Pazardzhik, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Stara Zagora, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Veliko Tarnovo, Bulgaria
Research Site
Vidin, Bulgaria
Sponsors and Collaborators
  More Information

Responsible Party: MC MD, AstraZeneca Identifier: NCT00984373     History of Changes
Other Study ID Numbers: NIS-NBG-SER-2009/1 
Study First Received: September 24, 2009
Last Updated: February 2, 2010
Health Authority: Bulgaria: Ministry of Health

Keywords provided by AstraZeneca:
Schizophrenia epidemiology
Schizophrenic patients' social and health characteristics

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders processed this record on October 20, 2016